About
/
Team
Company Leadership
Founder & Chief Executive Officer
Nawal is Founder and CEO of Holmusk, bringing more than fifteen years of finance and strategy consulting experience to the helm of the company. Prior to Holmusk, Nawal founded and led HelloPay (a Rocket Internet Venture), and spent time serving global clients at McKinsey & Company and Credit Suisse. Nawal drives the strategic direction of Holmusk, leading from the front with round-the-clock hustle and infectious energy.
Chief Growth Officer
Eze is Chief Growth Officer at Holmusk - Eze has nearly two decades of experience leading commercialization of data, analytics and consulting solutions supporting the life sciences and biopharma industries. He joins Holmusk after serving as the Vice President of New Products and Partnership with Optum Life Sciences and has held commercial leadership roles with Decision Resources Group (now part of Clarivate), IQVIA, and OptimizeRX.
SVP, Head of Product & Operations
Eileen is Head of Operations at Holmusk. She has over 15 years of experience in the software and medical device industries, with a focus on product innovation and product development lifecycle management. Before joining Holmusk, she worked at Stryker, a leading medical device company, where she successfully launched more than 10 Patient Care products, primarily for the North American and European markets. She is also experienced in business process reengineering. She has an Electrical Engineering degree from McGill University and an MBA from IE Business School.
Chief Technology Officer
Subra is Chief Technology Officer at Holmusk. A computer engineer by training, Subra drives our tech strategy and all new product development, and leads all compliance activities related to privacy and security. He is an enthusiastic Haskell evangelist, much to the dismay of people who end up talking to him.
Chief of Staff to CEO & President, Head of HR
Paul is Chief of Staff to Holmusk's CEO and President, and the head of HR. He has over 12 years of experience in leading health engagements. His focused has been on integrated health, population management, and data analytic solutions across Southeast Asia and the United States. With experience purposely balanced in strategy, analytics and client engagement, he has worked to drive behavioural and structural changes in the way patients interact and participate within the health ecosystems – striving to create better outcomes for individuals and systems delivering care.
SVP, Real-World Evidence
Nadia is Vice President of Real-World Evidence. She has over 10 years of experience in real-world data and their use in international health policy development, academic research, and commercial project delivery. She is an epidemiologist by training and has a PhD in Genetic epidemiology.
VP, Corporate Development
Sonali is Vice President of Corporate Development. Prior to Holmusk, she was Co-Founder and Chief Customer Officer of Patagonia Health. She led and provided strategic direction to sales, product management and customer success teams. She served numerous public health and behavioral health organization clients across the United States.
SVP, Pharma & Life Sciences Partnerships
Subina is SVP of Pharma and Life Sciences Partnerships. She has over 10 years of experience in the biopharma, medical device, and global public health sector. She previously worked at the Pharma & Life Sciences Consulting practice at PwC US, leading strategic and business transformation projects in R&D, medical affairs, and commercial operations. Prior to that, she worked as a medical device design engineer at Ethicon Endo-Surgery and MicroCube. Subina is a Biomedical Engineer by training with a MS from the University of Pennsylvania and a BS from the Georgia Institute of Technology.
Head Of Holmusk Europe
Stefan Suter is Head of Holmusk Europe. He has 2 decades of experience in healthcare industry across Europe and Asia with a deep understanding of healthcare systems. Stefan is the founder of Curo-Health, has worked at Roche and Novartis in finance and market access, heading up market access department Asia, while based in Singapore. Stefan is passionate about patient-centered care and personalized medicine. Bringing together different experiences and working in diverse cultures and environments to solve real-world problems has always been his zest and asset.
SVP, Clinical Data Strategy & Operations
Alex Vance is Holmusk's Senior Vice President of Clinical Data Strategy and Operations. He's worked at the intersection of clinical research, clinical practice, and tech-enabled solutions for the past 15 years. Prior to that, he worked as a mental health counselor and researcher.
VP, Real-World Data
Alex has more than two decades of experience building data and analytics solutions using some of the largest datasets in the healthcare industry. Before joining Holmusk, he previously worked at Optum where he designed and led development of research, data analytics, and population health platforms for Life Sciences and Healthcare Organizations. Prior to that, he built data solutions for large clients. Alex has a Computer Science degree from the University of Minnesota.
Strategic Advisor
Anand is a Strategic Advisor to Holmusk. He is a seasoned healthcare executive with 24 years of global drug development experience. An anesthesiologist by training, he qualified as a medical doctor at University College London. He spent 23 years at Quintiles, where he led the company’s expansion into India and subsequently helped build the business in Japan, Brazil and Peru before taking the company public on the NYSE in 2013. Anand went on to lead and grow the merged IQVIA businesses across Asia Pacific. He is a senior advisor to TPG Capital and is Chairman of Novotech Health Holdings.
Scientific Advisor
Christoph U. Correll is Professor of Psychiatry at The Zucker School of Medicine at Hofstra/ Northwell, New York, USA, and also Professor and Chair of the Department of Child and Adolescent Psychiatry, Charité University Medicine, Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City. Since 1997, he has been working and conducting research in New York, USA, and since 2017 he is also working in Germany again.
Scientific Advisor
John is a Scientific Advisor to Holmusk. He is an internationally renowned psychiatrist and was the primary investigator for the STAR*D study, the largest prospective clinical trial of Major Depressive Disorder ever conducted. He is a Professor Emeritus at the Duke-NUS Medical School, and adjunct professor of Psychiatry and Behavioral Sciences at Duke University School of Medicine. He has authored and edited over 10 books and over 600 scientific journal articles.
Chair of the Board
Michael is the Chair of the Board. He is Co-Founder and Managing Partner of Ardan Equity, a healthcare enterprise software private equity firm. Michael is Founding Chair of Phreesia (NYSE: PHR). Previously, he was Co-Founder and Managing Partner of Optum Ventures. Michael was Co-Founder and CEO of Humedica and following its acquisition by UnitedHealth Group he broadened his role within UHG as President and CEO of Optum Analytics. He also was CEO of PharMetrics, which was acquired by IMS Health (now IQVIA). Michael received his Bachelor’s Degree in Economics from Brandeis University and an MBA from Harvard Business School.
Board Member
Vijay a Board Member. Vijay began his career in medicine and worked as a doctor for the NHS. He qualified from Guy’s Kings and St. Thomas Medical School in London and holds a MBBS in Medicine and a B.S. in Development Neurobiology. He was previously a health care investment banker at Peel Hunt and Piper Jaffray, looking after listed health care clients as well as undertaking IPO, M&A, private placement and secondary fundraising transactions. He then became a healthcare investor, initially at an IP commercialisation company and a life science VC fund. Vijay has invested in data driven companies targeting respiratory health, complications of diabetes, patient safety, consent and education.
Board Member
May brings over 20 years of experience in investments and corporate strategy. She joined Heritas Capital from TPC (Tsao Pao Chee). As Managing Director of Investments, she was responsible for crafting and executing a sophisticated impact investment strategy including impact measurement and Environmental, Social and Governance (ESG) investment frameworks to drive the Group’s well-being vision into action. She also led venture investments at TPC, with a focus on social and industrial innovation investments.
Prior to TPC, she led global climate tech investments for GenZero, a S$5 billion private equity firm established by Temasek. At GenZero, she invested into decarbonization technologies and built robust ESG and climate impact frameworks. Before that, she drove sustainability and innovation efforts at SP Group, a leading energy utility company. She led initiatives in energy transition including establishing and leading venture investments. She also aligned the group’s business strategy with the UN Sustainable Development Goals (SDGs), and developed new ventures around cutting-edge sustainable technologies.
Earlier in her career, May held investment banking roles with JP Morgan in New York and Hong Kong, and served as a financial analyst with Fidelity Investments and Temasek in Boston and Singapore. May is deeply passionate about sustainable development and frequently contributes to thought leadership in the impact investing space.
Founder & Chief Executive Officer
Nawal is Founder and CEO of Holmusk, bringing more than fifteen years of finance and strategy consulting experience to the helm of the company. Prior to Holmusk, Nawal founded and led HelloPay (a Rocket Internet Venture), and spent time serving global clients at McKinsey & Company and Credit Suisse. Nawal drives the strategic direction of Holmusk, leading from the front with round-the-clock hustle and infectious energy.
Singapore
New York
London
Basel
Berlin